EUVIMEDEUVIMED entdecken
Fallbericht

Two cases of advanced melanoma with BRAF L597 mutation: Options for systemic treatment

Ryo Amagai iD, Taku Fujimura iD, Yumi Kambayashi iD, Manami Takahashi-Watanabe iD, Emi Yamazaki iD, Erika Tamabuchi, Kenta Oka, Yusuke Muto iD, Akira Hashimoto, Yoshihide Asano iD

The Journal of Dermatology · 2025

DOI: 10.1111/1346-8138.17718 ↗

Kurz gefasst

Fallbericht in der Zeitschrift The Journal of Dermatology, 2025. Verfasst von Ryo Amagai und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan. Hauptthemen laut MEDLINE: Melanoma, Proto-Oncogene Proteins B-raf, Skin Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The combination of BRAF and MEK kinase inhibitors is a well‐established treatment for BRAF V600‐mutated advanced melanoma. However, the efficacy of these therapies against less common BRAF mutations, such as BRAF L597, remains unclear. We report two cases of advanced melanoma harboring the BRAF L597 mutation. In the first case, a 77‐year‐old man with metastatic melanoma achieved complete remission following combination therapy with nivolumab and ipilimumab. In the second case, a 50‐year‐old woman with metastatic melanoma exhibited resistance to multiple systemic therapies, including nivolumab, ipilimumab, and targeted therapy with encorafenib and binimetinib. These cases highlight the variable therapeutic responses in melanoma with the BRAF L597 mutation, suggesting that immune checkpoint inhibitors may be a viable first‐line treatment, particularly for patients with a high tumor mutational burden. Further studies are needed to establish optimal treatment strategies for this rare mutation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaProto-Oncogene Proteins B-rafSkin NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedAgedMutationCarbamatesSulfonamidesBenzimidazolesNivolumabIpilimumabDrug Resistance, NeoplasmImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

BRAF L597 melanomaBRAF/MEK inhibitorimmune checkpoint inhibitortreatment

Substanzen

Proto-Oncogene Proteins B-rafBRAF protein, humanencorafenibCarbamatesSulfonamidesbinimetinibBenzimidazolesNivolumabIpilimumabImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.

ORCID-Profile: Ryo Amagai, Taku Fujimura, Yumi Kambayashi, Manami Takahashi-Watanabe, Emi Yamazaki, Yusuke Muto, Yoshihide Asano

Zitieren

APA

Amagai, R., Fujimura, T., Kambayashi, Y., Takahashi-Watanabe, M., Yamazaki, E., Tamabuchi, E., Oka, K., Muto, Y., Hashimoto, A., & Asano, Y. (2025). Two cases of advanced melanoma with BRAF L597 mutation: Options for systemic treatment. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17718

Vancouver

Amagai R, Fujimura T, Kambayashi Y, Takahashi-Watanabe M, Yamazaki E, Tamabuchi E, et al. Two cases of advanced melanoma with BRAF L597 mutation: Options for systemic treatment. The Journal of Dermatology. 2025. doi:10.1111/1346-8138.17718

BibTeX
@article{Amagai2025,
  author = {Amagai, Ryo and Fujimura, Taku and Kambayashi, Yumi and Takahashi-Watanabe, Manami and Yamazaki, Emi and Tamabuchi, Erika and Oka, Kenta and Muto, Yusuke and Hashimoto, Akira and Asano, Yoshihide},
  title = {Two cases of advanced melanoma with BRAF L597 mutation: Options for systemic treatment},
  journal = {The Journal of Dermatology},
  year = {2025},
  doi = {10.1111/1346-8138.17718}
}
Kostenlos starten →